CTXR - התחייבויות לטווח ארוך להון Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals relies on secured biological raw material supply chains for hospital needs to minimize shortages. An analysis of long-term debt-to-equity captures the impact of borrowings on asset value, with the ratio remaining around 0.11. Future growth is based on the certification of intensive care drugs and the successful commercial launch of a niche oncology portfolio.

The fundamental attractiveness of Citius Pharmaceuticals (CTXR) depends on the balance between borrowed funds and equity. This long-term financial stability metric compares liabilities with maturities exceeding one year against net assets. An increase in this ratio signals a growing credit burden on the business. Low values confirm the efficiency of outsourcing production and trials. The absence of capital expenditures minimizes the need for long-term loans, enhancing the company's stability.